STUDY OF THE CLINICAL EFFICACY OF THE PREPARATION “CELEXIB” IN THE TREATMENT OF ARTHRITIS AND ARTROSIS IN DOGS

Clinical studies were conducted to determine the effectiveness of the veterinary drug «Celexib» on dogs. One milliliter of the drug contains Сelecoxib - 100 mg. excipients: pyralidone-2. The drug is intended to reduce inflammation and pain in inflammatory and pain syndromes of various origins, in particular in acute and chronic diseases of the musculoskeletal system (fractures, injuries, sprains of ligaments and tendons, osteoarthritis, chronic degenerative joint diseases). It is also used as an analgesic and anti-inflammatory agent in complex therapy. The effectiveness of the studied drug «Celecoxib» was assessed by the dynamics of clinical and biochemical blood parameters of animals and a significant improvement in their condition with arthritis and arthrosis. The study was conducted in four veterinary clinics for carnivores in the city of Rivne. The veterinary drug «Celexib» (solution for injection) in terms of anti-inflammatory effect in the complex therapy of dogs suffering from arthritis is superior to the comparison drug «Simalgex». It has a positive effect on the clinical and biochemical blood parameters of treated dogs aged 2–5 years, since the incidence of animals decreased by 50.0% 2 weeks after the use of «Celexib», which is 25.0% lower than the indicators in the experimental group after the use of the comparison drug. It is worth noting that most of the average clinical and biochemical blood parameters of dogs in both experimental groups reached the physiological level on the 15th day of the experiment, and the rest (fibrinogen) only at the end of the experiment. Also the veterinary drug «Celexib» (solution for injection) showed an advantage in terms of anti-inflammatory effect in the complex therapy of dogs suffering from arthritis, compared to «Simalgex». It has a positive effect on the clinical and biochemical blood parameters of dogs aged 7–8 years. The incidence of animals after treatment with «Celexib» was 20.0% lower than after treatment with «Simalgex» after 15 days, and decreased to 20.0% on the 30th day relative to the initial values before treatment. In the group receiving the comparison drug, this indicator was 40%. It is worth noting that most of the average clinical and biochemical blood parameters of dogs in both experimental groups reached the limits of the physiological level on the 15th day of the experiment. The drug «Celexib» is recommended for dogs to reduce inflammation and pain in inflammatory and pain syndromes of various origins, in particular in acute and chronic diseases of the musculoskeletal system (arthritis and arthrosis). It can also be used as an analgesic and anti-inflammatory drug in complex therapy according to the instructions for use developed by LLC DEVIE.